733 related articles for article (PubMed ID: 32933565)
1. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
[TBL] [Abstract][Full Text] [Related]
2. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
3. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
4. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
5. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
6. PROTAC: A promising technology for cancer treatment.
Zhou X; Dong R; Zhang JY; Zheng X; Sun LP
Eur J Med Chem; 2020 Oct; 203():112539. PubMed ID: 32698111
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule PROTACs: novel agents for cancer therapy.
Wan Y; Yan C; Gao H; Liu T
Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
[TBL] [Abstract][Full Text] [Related]
8. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
An S; Fu L
EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
[TBL] [Abstract][Full Text] [Related]
10. Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer.
Barghout SH
Anticancer Agents Med Chem; 2021; 21(2):214-230. PubMed ID: 32275492
[TBL] [Abstract][Full Text] [Related]
11. Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development.
Lv M; Hu W; Zhang S; He L; Hu C; Yang S
Cancer Lett; 2022 Jul; 539():215716. PubMed ID: 35500825
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in PROTACs for Drug Targeted Protein Research.
Yao T; Xiao H; Wang H; Xu X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
[TBL] [Abstract][Full Text] [Related]
13. Proteolysis targeting chimeras (PROTACs) for epigenetics research.
Vogelmann A; Robaa D; Sippl W; Jung M
Curr Opin Chem Biol; 2020 Aug; 57():8-16. PubMed ID: 32146413
[TBL] [Abstract][Full Text] [Related]
14. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
[TBL] [Abstract][Full Text] [Related]
15. Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention.
Singh H; Agrawal DK
Future Med Chem; 2022 Oct; 14(19):1403-1416. PubMed ID: 36047364
[TBL] [Abstract][Full Text] [Related]
16. New-generation advanced PROTACs as potential therapeutic agents in cancer therapy.
Wang C; Zhang Y; Chen W; Wu Y; Xing D
Mol Cancer; 2024 May; 23(1):110. PubMed ID: 38773495
[TBL] [Abstract][Full Text] [Related]
17. PROTACs: past, present and future.
Li K; Crews CM
Chem Soc Rev; 2022 Jun; 51(12):5214-5236. PubMed ID: 35671157
[TBL] [Abstract][Full Text] [Related]
18. Targeted protein degradation: elements of PROTAC design.
Paiva SL; Crews CM
Curr Opin Chem Biol; 2019 Jun; 50():111-119. PubMed ID: 31004963
[TBL] [Abstract][Full Text] [Related]
19. Cancer Selective Target Degradation by Folate-Caged PROTACs.
Liu J; Chen H; Liu Y; Shen Y; Meng F; Kaniskan HÜ; Jin J; Wei W
J Am Chem Soc; 2021 May; 143(19):7380-7387. PubMed ID: 33970635
[TBL] [Abstract][Full Text] [Related]
20. Protacs for treatment of cancer.
Sakamoto KM
Pediatr Res; 2010 May; 67(5):505-8. PubMed ID: 20075761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
